AngioDynamics (NASDAQ:ANGO) Releases FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share guidance of ($0.38)-($0.34) for the period, compared to the consensus earnings per share estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY 2025 guidance to -0.380–0.340 EPS.

AngioDynamics Stock Performance

AngioDynamics stock opened at $12.94 on Friday. The business’s 50-day simple moving average is $8.12 and its two-hundred day simple moving average is $7.38. The company has a market cap of $525.80 million, a PE ratio of -2.12 and a beta of 0.59. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $13.13.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. During the same period in the previous year, the company posted ($0.05) earnings per share. AngioDynamics’s revenue for the quarter was down .1% on a year-over-year basis. As a group, analysts predict that AngioDynamics will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ANGO. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research report on Tuesday, December 10th. Canaccord Genuity Group dropped their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.